European Journal of Nuclear Medicine

, Volume 23, Issue 6, pp 693–696 | Cite as

Parathyroid scintigraphy: comparison of technetium-99m methoxyisobutylisonitrile and technetium-99m tetrofosmin studies

  • R. M. Aigner
  • G. F. Fueger
  • R. Nicoletti
Short Communication


We report the preliminary results of a prospective study demonstrating tetrofosmin uptake in surgically and histologically proven parathyroid adenomas. In ten patients with primary chronic hyperparathyroidism, parathyroid imaging was performed using (1) technetium-99m methoxyisobutylisonitrile (MIBI) and (2)99mTc-1,2-bis(bis(2-ethoxyethyl)phosphino)ethane (tetrofosmin) within a time interval of 3–5 days. Both tracers correctly identified the parathyroid adenomas by focal prolonged tracer retention. On visual inspection image contrast was generally higher with MIBI than with tetrofosmin in all the patients studied. Tetrofosmin showed a slower elimination from the parathyroid adenomas than MIBI in six of the ten cases. Our preliminary results show that tetrofosmin, like MIBI, as a feasible, sensitive tracer for parathyroid scintigraphy. For routine use, the rapid kit preparation without heating and the lower radiation dose to the patient make tetrofosmin an alternative tracer for parathyroid scintigraphy. Further evaluation is needed to determine which of the two tracers is the more sensitive for the detection of parathyroid adenomas, and which tracer properties better reflect the degree of endocrine activity.[/p]

Key words

Technetium-99m methoxyisobutylisonitrile Technetium-99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane Parathyroid adenoma Hyperparathyroidism 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Casaraca D, Rubello D, Saladini G, etal. Clinical role of Tc99m-MIBI scintigraphy in parathyroid imaging, a comparative study with T1-201 scintigraphy, echography and CT.Eur J Nucl Med 1991; 18: 531.Google Scholar
  2. 2.
    Kelley JD, Forster AM, Higley B, etal. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging.J Nucl Med 1993; 34: 222–227.Google Scholar
  3. 3.
    Civelek AC, Durski K, Shafique I, etal. Failure of perchlorate to inhibit Tc-99m-isonitrile binding by the thyroid during myocardial perfusion studies.Clin Nucl Med 1991; 16: 358–361.Google Scholar
  4. 4.
    Piwicna-Worms D, Chin ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.Cancer Res 1993; 53: 977–984.Google Scholar
  5. 5.
    Sandrock D, Merino MJ, Norton JA, Neumann RD. Ultrastructural histology correlates with results of thallium201/technetium-99m parathyroid substration scintigraphy.J Nucl Med 1993; 34: 24–29.Google Scholar
  6. 6.
    Wackers FJ, Berman DJ, Maddahi J, Watson DD, Beller GA, Strauss HW Boucher CA, Picard M, Holman BL, Fridrich R, Inglese E, Delaloye B, Bischof-Delaloye A, Camin L, McKusik K. Technetium-99m-hexakis-2-methoxyisobutylisonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging.JNucl Med 1989; 30: 301–311.Google Scholar
  7. 7.
    Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study).J Nucl Med 1992; 33: 1801–1807.Google Scholar
  8. 8.
    O'Doherty JO, Kettle AG, Wells P, etal. Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies.J Nucl Med 1992; 33: 313.Google Scholar
  9. 9.
    Osmanagaoglu K, Schelstraete K, Lippens M, Obrie E, De Feyter I. Visualization of a parathyroid adenoma with Tc-99m MIBI in a case with iodine saturation and impaired tallium uptake.Clin Nucl Med 1993; 18: 214–216.Google Scholar
  10. 10.
    Higley B, Smith FW Smith T, Gemmell HG, etal. Technetium-99m-1,2bis(bis(2-ethoxy-ethyl)phosphino)ethane: human biodistribution, dosimetry, and safety of a new myocardial perfusion imaging agent.J Nucl Med 1993; 34: 30–38.Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • R. M. Aigner
    • 1
  • G. F. Fueger
    • 1
  • R. Nicoletti
    • 1
  1. 1.Division of Nuclear Medicine, Department of RadiologyUniversity Hospital GrazAustria

Personalised recommendations